Show simple item record

dc.contributor.authorBernabeu Morón, Ignacio 
dc.contributor.authorFajardo, Carmen
dc.contributor.authorMarazuela, Mónica
dc.contributor.authorCORDIDO CARBALLIDO, FERNANDO 
dc.contributor.authorVenegas, Eva María
dc.contributor.authorde Pablos-Velasco, Pedro
dc.contributor.authorMaroto, Gonzalo Piedrola
dc.contributor.authorOlvera, María Pilar
dc.contributor.authorde Paz, Isabel Pavón
dc.contributor.authorCarvalho, Davide
dc.contributor.authorRomero, Carme
dc.contributor.authorDe la Cruz, Guillermo
dc.contributor.authorEscolá, Cristina Álvarez
dc.date.accessioned2022-03-08T08:48:57Z
dc.date.available2022-03-08T08:48:57Z
dc.date.issued2020
dc.identifier.issn1355-008X
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32725444es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16188
dc.description.abstractPURPOSE: Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice. METHODS: Cross-sectional, multicentre, observational study conducted to determine the effectiveness-measured by control of serum insulin-like growth factor 1 (IGF-1)-of lanreotide autogel 120 mg at dosing intervals >4 weeks for >/=6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were excluded. RESULTS: Among 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0 [74.5], 95% CI: 160.8 -189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment (n = 81). GH levels were </=2.5 and </=1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5-6 (57.8%) or 7-8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1). The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed injections) was 94.5%. CONCLUSION: Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshMiddle Aged *
dc.subject.meshInsulin-Like Growth Factor I *
dc.subject.meshHumans *
dc.subject.meshCross-Sectional Studies *
dc.subject.meshQuality of Life *
dc.titleEffectiveness of lanreotide autogel 120?mg at extended dosing intervals for acromegalyen
dc.typeJournal Articlees
dc.authorsophosBernabéu, Ignacio;Fajardo, Carmen;Marazuela, Mónica;Cordido, Fernando;Venegas, Eva María;de Pablos-Velasco, Pedro;Maroto, Gonzalo Piedrola;Olvera, María Pilar;de Paz, Isabel Pavón;Carvalho, Davide;Romero, Carme;De la Cruz, Guillermo;Escolá, Cristina Álvarez
dc.identifier.doi10.1007/s12020-020-02424-z
dc.identifier.pmid32725444
dc.identifier.sophos35760
dc.issue.number3es
dc.journal.titleENDOCRINEes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Endocrinoloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Endocrinoloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Biomédica da Coruña (INIBIC)es
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674328/pdf/12020://2020://Article://2424.pdfes
dc.rights.accessRightsopenAccess
dc.subject.decsfactor I de crecimiento insulinoide *
dc.subject.decsmediana edad *
dc.subject.decshumanos *
dc.subject.decsestudios transversales *
dc.subject.decscalidad de vida *
dc.subject.keywordCHUACes
dc.subject.keywordCHUSes
dc.subject.keywordINIBICes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number70es


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional